Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

12/07/2012 | 08:00am US/Eastern

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
React to this article
Latest news
Date Title
05:20a CHINA OILFIELD SERVICES : COSL promotes overseas technical services of high-end logging equipment
05:10a SOLAR A/S : No. 11 2015 Share trading in Solar
05:05a AMERICAN HERITAGE : Miami Northwestern dominates at Miramar Relays
05:03a AIR CANADA : Twenty five in hospital after Air Canada flight slides off Halifax runway
04:55a EVA AIRWAYS : Air to open flight services between Kaohsiung, Fukuoka
04:55a DAISO : Checks continue on foods from NE Japan
04:51a WHOLE FOODS MARKET : From stock options to oranges: Whole Foods Rewards is a natural for growth
04:51a INTEL : lists job opening for cryptocurrency researcher
04:51a GAMESTOP : buying customer gift cards issued by other retailers
04:51a BURBERRY : Making a 'lovemark': How Coke and Burberry derive devotion digitally
Latest news
Advertisement
Hot News 
JUDGES SCIENTIFIC : Profit Up But Like-For-Like Revenue Shrinks
MELROSE BANCORP : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
OHR PHARMACEUTICAL : Announces Final Topline Data From OHR-102 Phase II IMPACT Study in Wet-AMD
ANDREWS SYKES : Temporary arena in London requires replacement heating
RBC BEARINGS : Nasdaq stocks posting largest percentage increases
Most Read News
03/28 F SECURE : Hypponen Reviews the State of the Internet
03/28 SHAFTESBURY : Big trouble in little Chinatown as rent rises force restaurant owners out
03/28 KROGER : Legislators smacked with hard questions
03/28 PG&E6CPREF : PG&E helps Salvation Army with mobile vehicle
03/28 GLAXOSMITHKLINE : GSK statement on meningitis vaccination in the UK
Most recommended articles
04:45a ChemChina chairman says hopes to re-list Pirelli in Italy
04:43aDJAIRBUS : Philippine Airlines Orders 2 More A321 NEOs from Airbus
04:24a U.S. jobs to add heat to Fed lift-off debate
04:12a German state workers win two-stage pay rise of more than 4 percent
04:07a Denmark applies to join China-backed AIIB investment bank
Dynamic quotes  
ON
| OFF